Fenofibrate NDC 60505-3121

NDC codes

FDA NDC Directory

Product NDC (as listed)60505-3121Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60505-3121Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
60505-3121-1	60505312101	100 CAPSULE in 1 BOTTLE (60505-3121-1)Marketed from Jul 26, 2013
60505-3121-3	60505312103	30 CAPSULE in 1 BOTTLE (60505-3121-3)Marketed from Jul 26, 2013
60505-3121-5	60505312105	500 CAPSULE in 1 BOTTLE (60505-3121-5)Marketed from Jul 26, 2013
60505-3121-9	60505312109	90 CAPSULE in 1 BOTTLE (60505-3121-9)Marketed from Jul 26, 2013

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fenofibrate
Generic name (nonproprietary): fenofibrate
Active ingredients: Fenofibrate — 130 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Apotex Corp.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202252
Marketing start: Jul 26, 2013
Listing expires: Dec 31, 2026
Identifiers: Product ID 60505-3121_81d94e71-5260-d81d-f3b9-070ec3c0743aSPL ID 81d94e71-5260-d81d-f3b9-070ec3c0743aSPL set ID 68024459-987a-9cf4-f539-4959093bc9f0RxCUI 483425, 483427UNII U202363UOSUPC 0360505312139, 0360505312030
Pharmacologic class: Peroxisome Proliferator Receptor alpha Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460505312101 followed by a unit qualifier and the quantity

Package 60505-3121-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Oct 29, 2025.

Indications (excerpt from the label)

Fenofibrate capsules, USP are indicated as adjunctive therapy to diet: to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL). to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible. Limitations of Use Markedly elevated levels of serum TG (e.g., >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been determined [see Warnings and Precautions (5.7)] . Fenofibrate did not reduce coronary heart disease morbidity and mortality in two large, randomized …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)